181 related articles for article (PubMed ID: 33543397)
41. Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients.
Bouazza N; Tréluyer JM; Ottolenghi C; Urien S; Deschenes G; Ricquier D; Niaudet P; Chadefaux-Vekemans B
Orphanet J Rare Dis; 2011 Dec; 6():86. PubMed ID: 22195601
[TBL] [Abstract][Full Text] [Related]
42. Parenchymal organ cystine depletion with long-term cysteamine therapy.
Gahl WA; Charnas L; Markello TC; Bernardini I; Ishak KG; Dalakas MC
Biochem Med Metab Biol; 1992 Dec; 48(3):275-85. PubMed ID: 1476793
[TBL] [Abstract][Full Text] [Related]
43. Recent Research in Ocular Cystinosis: Drug Delivery Systems, Cysteamine Detection Methods and Future Perspectives.
Castro-Balado A; Mondelo-García C; Varela-Rey I; Moreda-Vizcaíno B; Sierra-Sánchez JF; Rodríguez-Ares MT; Hermelo-Vidal G; Zarra-Ferro I; González-Barcia M; Yebra-Pimentel E; Giráldez-Fernández MJ; Otero-Espinar FJ; Fernández-Ferreiro A
Pharmaceutics; 2020 Dec; 12(12):. PubMed ID: 33287176
[TBL] [Abstract][Full Text] [Related]
44. Novel approaches for improving stability of cysteamine formulations.
Dixon P; Powell K; Chauhan A
Int J Pharm; 2018 Oct; 549(1-2):466-475. PubMed ID: 30099213
[TBL] [Abstract][Full Text] [Related]
45. Evolution of ocular manifestations in nephropathic cystinosis: a long-term study of a population treated with cysteamine.
Dureau P; Broyer M; Dufier JL
J Pediatr Ophthalmol Strabismus; 2003; 40(3):142-6. PubMed ID: 12795432
[TBL] [Abstract][Full Text] [Related]
46. Understanding intestinal cysteamine bitartrate absorption.
Dohil R; Fidler M; Barshop BA; Gangoiti J; Deutsch R; Martin M; Schneider JA
J Pediatr; 2006 Jun; 148(6):764-9. PubMed ID: 16769383
[TBL] [Abstract][Full Text] [Related]
47. Follow-up and treatment of adults with cystinosis in the Netherlands.
Geelen JM; Monnens LA; Levtchenko EN
Nephrol Dial Transplant; 2002 Oct; 17(10):1766-70. PubMed ID: 12270982
[TBL] [Abstract][Full Text] [Related]
48. A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis.
Armas D; Holt RJ; Confer NF; Checani GC; Obaidi M; Xie Y; Brannagan M
Adv Ther; 2018 Feb; 35(2):199-209. PubMed ID: 29411268
[TBL] [Abstract][Full Text] [Related]
49. Use of Human Induced Pluripotent Stem Cells and Kidney Organoids To Develop a Cysteamine/mTOR Inhibition Combination Therapy for Cystinosis.
Hollywood JA; Przepiorski A; D'Souza RF; Sreebhavan S; Wolvetang EJ; Harrison PT; Davidson AJ; Holm TM
J Am Soc Nephrol; 2020 May; 31(5):962-982. PubMed ID: 32198276
[TBL] [Abstract][Full Text] [Related]
50. Carbon Black Tinted Contact Lenses for Reduction of Photophobia in Cystinosis Patients.
Dixon P; Chauhan A
Curr Eye Res; 2019 May; 44(5):497-504. PubMed ID: 30624086
[TBL] [Abstract][Full Text] [Related]
51. Cysteamine prevents inhibition of adenylate kinase caused by cystine in rat brain cortex.
Figueiredo VC; Feksa LR; Wannmacher CM
Metab Brain Dis; 2009 Dec; 24(4):723-31. PubMed ID: 19437111
[TBL] [Abstract][Full Text] [Related]
52. Cysteamin eyedrops in three patients with nephropathic cystinosis.
Blanksma LJ; Jansonius NM; Reitsma-Bierens WC
Doc Ophthalmol; 1996-1997; 92(1):51-3. PubMed ID: 9181332
[No Abstract] [Full Text] [Related]
53. Twice-daily cysteamine bitartrate therapy for children with cystinosis.
Dohil R; Fidler M; Gangoiti JA; Kaskel F; Schneider JA; Barshop BA
J Pediatr; 2010 Jan; 156(1):71-75.e1-3. PubMed ID: 19775699
[TBL] [Abstract][Full Text] [Related]
54. Negligible urinary cysteamine loss in cystinosis patients with Fanconi syndrome.
Levtchenko EN; de Graaf-Hess A; Blom HJ; Monnens LA
Clin Nephrol; 2002 May; 57(5):349-51. PubMed ID: 12036193
[TBL] [Abstract][Full Text] [Related]
55. Limitations and Challenges in the Stability of Cysteamine Eye Drop Compounded Formulations.
Martín-Sabroso C; Alonso-González M; Fernández-Carballido A; Aparicio-Blanco J; Córdoba-Díaz D; Navarro-García F; Córdoba-Díaz M; Torres-Suárez AI
Pharmaceuticals (Basel); 2021 Dec; 15(1):. PubMed ID: 35056058
[TBL] [Abstract][Full Text] [Related]
56. [Cystinosis : Diagnosis, cystine-depleting therapy, and transition].
Kaufeld J; Weber LT; Kurschat C; Canaan-Kuehl S; Brand E; Oh J; Pape L
Internist (Berl); 2018 Aug; 59(8):861-867. PubMed ID: 29671012
[TBL] [Abstract][Full Text] [Related]
57. Cysteamine in renal transplantation: A report of two patients with nephropathic cystinosis and the successful re-initiation of cysteamine therapy during the immediate post-transplant period.
Berryhill A; Bhamre S; Chaudhuri A; Concepcion W; Grimm PC
Pediatr Transplant; 2016 Feb; 20(1):141-5. PubMed ID: 26477696
[TBL] [Abstract][Full Text] [Related]
58. Ocular manifestations of intermediate cystinosis: To treat or not to treat?
Sousa-Neves F; Ribeiro AC; Saraiva E; Ribeiro L; Sequeira J; Varandas R
Eur J Ophthalmol; 2020 Nov; 30(6):NP7-NP10. PubMed ID: 31074291
[TBL] [Abstract][Full Text] [Related]
59. Formulation and in vitro evaluation of cysteamine hydrochloride viscous solutions for the treatment of corneal cystinosis.
Bozdağ S; Gümüş K; Gümüş O; Unlü N
Eur J Pharm Biopharm; 2008 Sep; 70(1):260-9. PubMed ID: 18590953
[TBL] [Abstract][Full Text] [Related]
60. Nephropathic cystinosis: ineffectiveness of cysteamine therapy for ocular changes.
Cantani A; Giardini O; Ciarnella Cantani A
Am J Ophthalmol; 1983 May; 95(5):713-4. PubMed ID: 6846466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
